{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T19:46:10Z","timestamp":1762458370493},"reference-count":59,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2003,4,1]],"date-time":"2003-04-01T00:00:00Z","timestamp":1049155200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2003,4]]},"DOI":"10.1053\/sonc.2003.50039","type":"journal-article","created":{"date-parts":[[2003,4,28]],"date-time":"2003-04-28T19:53:00Z","timestamp":1051559580000},"page":"121-126","source":"Crossref","is-referenced-by-count":78,"title":["Treatment recommendations in Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia"],"prefix":"10.1053","volume":"30","author":[{"given":"Morie A.","family":"Gertz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Athanasios","family":"Anagnostopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew R.","family":"Branagan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morton","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stanley R.","family":"Frankel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Giralt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Todd","family":"Levine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikhil","family":"Munshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Pestronk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Rajkumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven P.","family":"Treon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/sonc.2003.50039_bib1","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1046\/j.1365-2141.2000.01918.x","article-title":"Waldenstrom's macroglobulinemia: A prospective study comparing daily with intermittent oral chlorambucil","volume":"108","author":"Kyle","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1053\/sonc.2003.50039_bib2","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1136\/jcp.19.1.55","article-title":"Waldenstrom's macroglobulinemia treated with cyclophosphamide and chlorambucil","volume":"19","author":"Buckle","year":"1996","journal-title":"J Clin Pathol"},{"key":"10.1053\/sonc.2003.50039_bib3","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1182\/blood.V75.10.1928.1928","article-title":"Fludarabine therapy in macroglobulinemic lymphoma","volume":"15","author":"Kantarjian","year":"1990","journal-title":"Blood"},{"key":"10.1053\/sonc.2003.50039_bib4","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/0002-9343(93)90231-D","article-title":"Fludarabine therapy in Waldenstrom's macroglobulinemia","volume":"95","author":"Dimopoulos","year":"1993","journal-title":"Am J Med"},{"key":"10.1053\/sonc.2003.50039_bib5","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1600-0609.1995.tb01779.x","article-title":"Fludarabine treatment in resistant Waldenstrom's macroglobulinemia","volume":"54","author":"Zinzani","year":"1995","journal-title":"Eur J Haematol"},{"key":"10.1053\/sonc.2003.50039_bib6","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1200\/JCO.1998.16.6.2060","article-title":"Activity of fludarabine in previously treated Waldenstrom's macroglobulinemia: A report of 71 cases. Groupe Cooperatif Macroglobulinemie","volume":"16","author":"Leblond","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1053\/sonc.2003.50039_bib7","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1007\/s002770000185","article-title":"Fludarabine therapy in Waldenstrom's macroglobulinemia","volume":"79","author":"Thalhammer-Scherrer","year":"2000","journal-title":"Ann Hematol"},{"key":"10.1053\/sonc.2003.50039_bib8","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1200\/JCO.1999.17.2.546","article-title":"Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenstrom's macroglobulinemia, and mantle-cell lymphoma","volume":"17","author":"Foran","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1053\/sonc.2003.50039_bib9","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1182\/blood.V98.1.41","article-title":"Prognostic factors and response to fludarabine therapy in patients with Waldenstrom macroglobulinemia: Results of United States intergroup trial (Southwest Oncology Group S9003)","volume":"98","author":"Dhodapkar","year":"2001","journal-title":"Blood"},{"key":"10.1053\/sonc.2003.50039_bib10","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1159\/000218466","article-title":"Fludarabine is an effective agent in immunocytic lymphoma","volume":"17","author":"Fenchel","year":"1994","journal-title":"Onkologie"},{"key":"10.1053\/sonc.2003.50039_bib11","doi-asserted-by":"crossref","first-page":"195","DOI":"10.7326\/0003-4819-118-3-199302010-00007","article-title":"Treatment of Waldenstrom macroglobulinemia with 2-chlorodeoxyadenosine","volume":"118","author":"Dimopoulos","year":"1993","journal-title":"Ann Intern Med"},{"key":"10.1053\/sonc.2003.50039_bib12","first-page":"317","article-title":"2-Chlorodeoxyadenosine therapy in Waldenstrom's macroglobulinaemia","volume":"36","author":"Delannoy","year":"1994","journal-title":"Nouv Rev Fr Hematol"},{"key":"10.1053\/sonc.2003.50039_bib13","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1600-0609.1999.tb01848.x","article-title":"Effect of a 2-hour infusion of 2-chlorodeoxyadenosine in the treatment of refractory or previously untreated Waldenstrom's macroglobulinemia","volume":"63","author":"Hellmann","year":"1999","journal-title":"Eur J Haematol"},{"key":"10.1053\/sonc.2003.50039_bib14","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1093\/oxfordjournals.annonc.a058811","article-title":"2-Chlorodeoxyadenosine therapy of patients with Waldenstrom macroglobulinemia previously treated with fludarabine","volume":"5","author":"Dimopoulos","year":"1994","journal-title":"Ann Oncol"},{"key":"10.1053\/sonc.2003.50039_bib15","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1089\/cbr.1999.14.241","article-title":"Rituximab immunotherapy for non-Hodgkin's lymphoma","volume":"14","author":"White","year":"1999","journal-title":"Cancer Biother Radiopharm"},{"issue":"suppl 12","key":"10.1053\/sonc.2003.50039_bib16","first-page":"79","article-title":"The use of rituximab in the treatment of malignant and nonmalignant plasma cell disorders","volume":"27","author":"Treon","year":"2000","journal-title":"Semin Oncol"},{"key":"10.1053\/sonc.2003.50039_bib17","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/00002371-200105000-00012","article-title":"CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia","volume":"24","author":"Treon","year":"2001","journal-title":"J Immunother"},{"key":"10.1053\/sonc.2003.50039_bib18","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1023\/A:1008350208019","article-title":"Rituximab therapy in Waldenstrom's macroglobulinemia: Preliminary evidence of clinical activity","volume":"10","author":"Byrd","year":"1999","journal-title":"Ann Oncol"},{"issue":"suppl 14","key":"10.1053\/sonc.2003.50039_bib19","first-page":"97","article-title":"Treatment of plasma cell dyscrasias by antibody-mediated immunotherapy","volume":"26","author":"Treon","year":"1999","journal-title":"Semin Oncol"},{"key":"10.1053\/sonc.2003.50039_bib20","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1200\/JCO.2002.09.039","article-title":"Treatment of Waldenstrom's macroglobulinemia with rituximab","volume":"20","author":"Dimopoulos","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1053\/sonc.2003.50039_bib21","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1600-0609.1998.tb01055.x","article-title":"Evaluation of marrow and blood haemopoietic progenitors in chronic lymphocytic leukaemia before and after chemotherapy","volume":"61","author":"Sala","year":"1998","journal-title":"Eur J Haematol"},{"key":"10.1053\/sonc.2003.50039_bib22","doi-asserted-by":"crossref","first-page":"3970","DOI":"10.1182\/blood.V86.10.3970.bloodjournal86103970","article-title":"Autologous progenitor cell transplantation: prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts","volume":"86","author":"Dreger","year":"1995","journal-title":"Blood"},{"key":"10.1053\/sonc.2003.50039_bib23","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1517\/14656566.2.6.945","article-title":"Treatment options in Waldenstrom's macroglobulinaemia: The role of the purine analogues","volume":"2","author":"Owen","year":"2001","journal-title":"Expert Opin Pharmacother"},{"key":"10.1053\/sonc.2003.50039_bib24","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJM199402033300504","article-title":"Lack of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapy","volume":"330","author":"O'Brien","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1053\/sonc.2003.50039_bib25","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1056\/NEJM199303183281116","article-title":"2-Chlorodeoxyadenosine for patients with B-cell chronic lymphocytic leukemia resistant to fludarabine","volume":"328","author":"Delannoy","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1053\/sonc.2003.50039_bib26","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1056\/NEJM199210083271504","article-title":"Response to 2-chlorodeoxyadenosine in patients with B-cell chronic lymphocytic leukemia resistant to fludarabine","volume":"327","author":"Juliusson","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1053\/sonc.2003.50039_bib27","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1038\/sj.bjc.6690195","article-title":"Cladribine with cyclophosphamide and prednisone in the management of low-grade lymphoproliferative malignancies","volume":"79","author":"Laurencet","year":"1999","journal-title":"Br J Cancer"},{"key":"10.1053\/sonc.2003.50039_bib28","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1038\/sj.leu.2401783","article-title":"Phase I\/II study of 2-chloro-2\u2032-deoxyadenosine with cyclophosphamide in patients with pretreated B cell chronic lymphocytic leukemia and indolent non-Hodgkin's lymphoma","volume":"14","author":"Van Den Neste","year":"2000","journal-title":"Leukemia"},{"key":"10.1053\/sonc.2003.50039_bib29","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1080\/10428190127502","article-title":"Rituximab toxicity in patients with peripheral blood malignant B-cell lymphocytosis","volume":"42","author":"Kanelli","year":"2001","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/sonc.2003.50039_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/07357909109032794","article-title":"Waldenstrom's macroglobulinemia: Long-term results with the M-2 protocol","volume":"9","author":"Case","year":"1991","journal-title":"Cancer Invest"},{"key":"10.1053\/sonc.2003.50039_bib31","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1038\/sj.bmt.1703041","article-title":"High-dose chemotherapy followed by stem cell transplantation in patients with resistant Waldenstrom's macroglobulinemia","volume":"27","author":"Anagnostopoulos","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"10.1053\/sonc.2003.50039_bib32","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1046\/j.1365-2141.1999.01461.x","article-title":"High-dose therapy with autologous haemopoietic stem cell support for Waldenstrom's macroglobulinaemia","volume":"105","author":"Desikan","year":"1999","journal-title":"Br J Haematol"},{"key":"10.1053\/sonc.2003.50039_bib33","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/sj.bmt.1701992","article-title":"Autologous peripheral blood stem cell transplantation for Waldenstrom's macroglobulinemia","volume":"24","author":"Yang","year":"1999","journal-title":"Bone Marrow Transplant"},{"key":"10.1053\/sonc.2003.50039_bib34","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1046\/j.1365-2141.2001.02873-5.x","article-title":"Thalidomide and low-dose dexamethasone in myeloma treatment","volume":"114","author":"Myers","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1053\/sonc.2003.50039_bib35","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1023\/A:1011132808904","article-title":"Thalidomide and dexamethasone combination for refractory multiple myeloma","volume":"12","author":"Dimopoulos","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1053\/sonc.2003.50039_bib36","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1080\/1042819021000006303","article-title":"BLT-D (clarithromycin [Biaxin], low-dose thalidomide, and dexamethasone) for treatment of myeloma and Waldenstrom's macroglobulinemia","volume":"43","author":"Coleman","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/sonc.2003.50039_bib37","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1445-5994.1988.tb02249.x","article-title":"Treatment of resistant Waldenstrom's macroglobulinemia with high dose glucocorticosteroids","volume":"18","author":"Jane","year":"1988","journal-title":"Aust NZ J Med"},{"key":"10.1053\/sonc.2003.50039_bib38","doi-asserted-by":"crossref","first-page":"3596","DOI":"10.1200\/JCO.2001.19.16.3596","article-title":"Treatment of Waldenstrom's macroglobulinemia with thalidomide","volume":"19","author":"Dimopoulos","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1053\/sonc.2003.50039_bib39","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1038\/sj.bmt.1703580","article-title":"Stem cell transplantation (SCT) for Waldenstrom's macroglobulinemia (WM)","volume":"29","author":"Anagnostopoulos","year":"2002","journal-title":"Bone Marrow Transplant"},{"key":"10.1053\/sonc.2003.50039_bib40","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/sj.bmt.1703190","article-title":"Successful non-myeloablative allogeneic peripheral blood stem cell transplantation (PBSCT) for Waldenstrom's macroglobulinemia with severe pancytopenia","volume":"28","author":"Ueda","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"10.1053\/sonc.2003.50039_bib41","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/sj.bmt.1701633","article-title":"Allogeneic bone marrow transplantation for advanced Waldenstrom's macroglobulinemia","volume":"23","author":"Martino","year":"1999","journal-title":"Bone Marrow Transplant"},{"key":"10.1053\/sonc.2003.50039_bib42","doi-asserted-by":"crossref","first-page":"453","DOI":"10.7326\/0003-4819-131-6-199909210-00011","article-title":"Therapeutic plasma exchange: An update from the Canadian Apheresis Group","volume":"131","author":"Clark","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1053\/sonc.2003.50039_bib43","first-page":"135","article-title":"Plasma exchange in the long-term management of Waldenstrom's macroglobulinemia","volume":"117","author":"Buskard","year":"1977","journal-title":"Can Med Assoc J"},{"key":"10.1053\/sonc.2003.50039_bib44","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.0954-6820.1985.tb01646.x","article-title":"Plasmapheresis in hyperviscosity syndrome","volume":"217","author":"Avnstorp","year":"1985","journal-title":"Acta Med Scand"},{"key":"10.1053\/sonc.2003.50039_bib45","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s11940-001-0050-5","article-title":"Paraproteinemic neuropathy","volume":"3","author":"Wicklund","year":"2001","journal-title":"Curr Treat Options Neurol"},{"key":"10.1053\/sonc.2003.50039_bib46","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/(SICI)1098-1101(1999)14:3<149::AID-JCA8>3.0.CO;2-9","article-title":"Clinical features, evaluation, and treatment of patients with polyneuropathy associated with monoclonal gammopathy of undetermined significance (MGUS)","volume":"14","author":"Gorson","year":"1999","journal-title":"J Clin Apheresis"},{"key":"10.1053\/sonc.2003.50039_bib47","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/j.1600-0404.1998.tb00636.x","article-title":"Comparison of IgM-MGUS and IgG-MGUS polyneuropathy","volume":"97","author":"Simovic","year":"1998","journal-title":"Acta Neurol Scand"},{"key":"10.1053\/sonc.2003.50039_bib48","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1056\/NEJM199111213252105","article-title":"Plasma exchange in polyneuropathy associated with monoclonal gammopathy of undetermined significance","volume":"325","author":"Dyck","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1053\/sonc.2003.50039_bib49","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/00019052-199910000-00013","article-title":"Paraproteinemia and neuropathy","volume":"12","author":"Simmons","year":"1999","journal-title":"Curr Opin Neurol"},{"key":"10.1053\/sonc.2003.50039_bib50","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1001\/archneur.57.5.641","article-title":"Neuropathy, heredity, and monoclonal gammopathy","volume":"57","author":"Latov","year":"2000","journal-title":"Arch Neurol"},{"key":"10.1053\/sonc.2003.50039_bib51","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/(SICI)1097-4598(200002)23:2<150::AID-MUS2>3.0.CO;2-G","article-title":"Prognosis of neuropathy with monoclonal gammopathy","volume":"23","author":"Latov","year":"2000","journal-title":"Muscle Nerve"},{"key":"10.1053\/sonc.2003.50039_bib52","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1212\/WNL.52.8.1701","article-title":"IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using rituximab","volume":"52","author":"Levine","year":"1999","journal-title":"Neurology"},{"key":"10.1053\/sonc.2003.50039_bib53","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s11864-000-0055-4","article-title":"Symptomatic cryoglobulinemia","volume":"1","author":"Dispenzieri","year":"2000","journal-title":"Curr Treat Options Oncol"},{"key":"10.1053\/sonc.2003.50039_bib54","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1080\/030097400750002139","article-title":"Cryoglobulinemic vasculitis resistant to intermittent intravenous pulse cyclophosphamide therapy","volume":"29","author":"Lamprecht","year":"2000","journal-title":"Scand J Rheumatol"},{"key":"10.1053\/sonc.2003.50039_bib55","doi-asserted-by":"crossref","first-page":"564","DOI":"10.2169\/internalmedicine.39.564","article-title":"Cryofiltration and oral corticosteroids provide successful treatment for an elderly patient with cryoglobulinemic glomerulonephritis associated with hepatitis C virus infection","volume":"39","author":"Mori","year":"2000","journal-title":"Intern Med"},{"issue":"suppl 13","key":"10.1053\/sonc.2003.50039_bib56","first-page":"S191","article-title":"Guidelines for the management of essential mixed cryoglobulinemia","volume":"13","author":"Tavoni","year":"1995","journal-title":"Clin Exp Rheumatol"},{"key":"10.1053\/sonc.2003.50039_bib57","doi-asserted-by":"crossref","first-page":"387","DOI":"10.3109\/10428199709051789","article-title":"Durable remission after splenectomy for Waldenstrom's macroglobulinemia with massive splenomegaly in leukemic phase","volume":"26","author":"Takemori","year":"1997","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/sonc.2003.50039_bib58","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/ajh.2830480411","article-title":"Durable complete remission of macroglobulinemia after splenectomy: A report of two cases and review of the literature","volume":"48","author":"Humphrey","year":"1995","journal-title":"Am J Hematol"},{"key":"10.1053\/sonc.2003.50039_bib59","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/ajh.2830370221","article-title":"Splenectomy for a case with Waldenstrom macroglobulinemia with giant splenomegaly","volume":"37","author":"Nagai","year":"1991","journal-title":"Am J Hematol"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009377540370061X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009377540370061X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,3,19]],"date-time":"2020-03-19T16:05:54Z","timestamp":1584633954000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009377540370061X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,4]]},"references-count":59,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2003,4]]}},"alternative-id":["S009377540370061X"],"URL":"https:\/\/doi.org\/10.1053\/sonc.2003.50039","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2003,4]]}}}